A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer

Contrast-Enhanced Mammography With Early and Delayed Acquisitions in the Assessment of the Extent of Residual Disease Following Neoadjuvant Treatment in Patients With Breast Cancer

The purpose of this study is to find out whether Contrast-Enhanced Mammography/CEM scans performed 2 minutes and 6 minutes after receiving Iohexol contrast dye can be used to identify the amount of residual disease in the breast following neoadjuvant treatment.

Inclusion Criteria:

• Any women >18 years of age at time of informed consent
• Diagnosed with breast cancer and schedule for NAT

Exclusion Criteria:

• History of kidney disease, creatinine level >1.3 or eGFR <45.
• Known allergic reaction to gadolinium or iodinated contrast media.
• Contraindication to contrast-enhanced breast MRI.
• Lesion not included in the field of view of either pre- or post-NAT MRI or CEM
• Presence of pacemakers or automated implantable cardioverter defibrilator
• Pregnant women